PMFA
CYTK icon

Plante Moran Financial Advisors’s Cytokinetics CYTK Stock Holding History

Plante Moran Financial Advisors’s Portfolio CYTK Stock Details CYTK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$85 Buy
+1
New +$72 ﹤0.01% 1552
2026
Q1 		– Sell
-13
Closed -$826 – 758
2025
Q4 		$826 Buy
+13
New +$809 ﹤0.01% 752

Other funds holding CYTK

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Plante Moran Financial Advisors's CYTK Position: Q2 2026 in Review

Plante Moran Financial Advisors opened a new position in Cytokinetics (CYTK) in Q2 2026: 1 share worth $85. The stake represents ﹤0.01% of the portfolio and ranks #1552 among its holdings. This is a return to the name: Plante Moran Financial Advisors previously reported a position in CYTK as recently as Q4 2025.

Plante Moran Financial Advisors first reported a position in CYTK in Q4 2025 and has held it in 2 quarters since. The position peaked at $826 in Q4 2025. 482 funds tracked by Wall St. Rank hold CYTK as of Q2 2026.

  • Plante Moran Financial Advisors held 1 share of Cytokinetics worth $85 as of Q2 2026.
  • Cytokinetics was a new Plante Moran Financial Advisors position in Q2 2026.
  • Cytokinetics made up ﹤0.01% of Plante Moran Financial Advisors's portfolio in Q2 2026, its #1552 holding.
  • Plante Moran Financial Advisors first reported a position in Cytokinetics in Q4 2025 and has held it in 2 quarters since.
  • Plante Moran Financial Advisors's Cytokinetics position peaked at $826 in Q4 2025.
  • 482 funds tracked by Wall St. Rank held Cytokinetics as of Q2 2026.

Based on Plante Moran Financial Advisors's 13F filing for Q2 2026, filed 6 Aug 2026.